research Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results
5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.
Search
for
Sort by
Research
120-150 / 1000+ results research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
research Administration of dutasteride in animal models of retinitis pigmentosa
Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
research Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
research Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
research Cardiovascular Toxicities of Androgen Deprivation Therapy
ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
research Finasteride inhibits epinephrine synthesis in humans: implication for sexual dysfunction
Finasteride may cause sexual dysfunction by reducing epinephrine levels.
research Cellular actions of testosterone in vascular cells: Mechanism independent of aromatization to estradiol
Testosterone affects vascular cells directly without converting to estradiol.
research 5 Alpha-Reductase Inhibitor
5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
research A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research 5α‐Reductase Inhibitors
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
research Chemical Mechanism of the Covalent Modification of 5.alpha.-Reductases by Finasteride as Probed by Secondary Tritium Isotope Effects
Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
research 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
research Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone.
GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research Finasteride Blocks the Reduction in Ictal Activity Produced by Exogenous Estrous Cyclicity
![Synthesis of Spiro[cyclohexane-1,2'-[2H]indene] Derivatives as Inhibitors of Steroid 5α-Reductase](/images/research/d91300a7-4d66-4d2c-90ac-293b0dbc5ff5/small/21048.jpg)
research Synthesis of Spiro[cyclohexane-1,2?-[2H]indene] derivatives as inhibitors of steroid 5?-reductase
Compound 15a was effective in inhibiting 5α-reductase.
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
research Natural Product-InspiredBis(trifluoromethyl) PhenylHydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitorsof Human Steroid 5α-Reductase Type-1: Synthesis, InVitro, and In Silico Studies
Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
research A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition, and Metabolic Profile in Transmen
Testosterone with dutasteride improves muscle strength and body composition in trans men.
research Doxazosin + finasteride in BPH with TPV ??? 25mL
research Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
research Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor
New hybrid compound found to effectively prevent hair loss.
research Nanomilled Oral Testosterone Plus Dutasteride Effectively Normalizes Serum Testosterone in Normal Men With Induced Hypogonadism
A combination of nanomilled oral testosterone and dutasteride normalized testosterone levels in men with low testosterone and is safe for short-term use.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
research 5α-reductase isoenzymes mediate stress-exacerbated Tourette-like responses in animal models
Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.
research Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota
Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.